Flows and flaws in primary central nervous system lymphoma

Nature Reviews Clinical Oncology

Volumn 7, Issue 8, 2010, Pages

  Ferreri, Andrés J M ^a   Illerhaus, Gerald ^b   Zucca, Emanuele ^c   Cavalli, Franco ^c  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b UNIVERSITY OF FREIBURG   (Germany)

^c OSPEDALE SAN GIOVANNI   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CARMUSTINE; CYTARABINE; METHOTREXATE; RITUXIMAB; THIOTEPA; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIMETABOLITE;

AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER RADIOTHERAPY; CANCER REGRESSION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG EFFICACY; DRUG TOLERABILITY; EVIDENCE BASED MEDICINE; HUMAN; LETTER; LEUKOENCEPHALOPATHY; MEDICAL DECISION MAKING; MULTIPLE CYCLE TREATMENT; PATIENT SELECTION; PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK BENEFIT ANALYSIS; TREATMENT OUTCOME; ALGORITHM; CENTRAL NERVOUS SYSTEM TUMOR; DECISION MAKING; DRUG COMBINATION; NONHODGKIN LYMPHOMA; NOTE; PATHOLOGY;

ALGORITHMS; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; CENTRAL NERVOUS SYSTEM NEOPLASMS; CYTARABINE; DECISION MAKING; DRUG THERAPY, COMBINATION; HUMANS; LYMPHOMA, NON-HODGKIN; METHOTREXATE; TREATMENT OUTCOME;

EID: 77955149232     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2010.9-c1     Document Type: Letter

References (10)

1. Ansell, S. M. and Rajkumar, S. V. Trials and tribulations in primary CNS lymphoma. Nat. Rev. Clin. Oncol. 7, 125-126 (2010).
2. Ferreri, A. J., Crocchiolo, R., Assanelli, A., Govi, S. and Reni, M. High-dose chemotherapy supported by autologous stem cell transplantation in patients with primary central nervous system lymphoma: facts and opinions. Leuk. Lymphoma 49, 2042-2047 (2008).
3. Illerhaus, G. et al. High-dose chemotherapy and autologous stem-cell transplantation without consolidating radiotherapy as first-line treatment for primary lymphoma of the central nervous system. Haematologica 93, 147-148 (2008).
4. Montemurro, M. et al. Primary central nervous system lymphoma treated with high-dose methotrexate, high-dose busulfan/thiotepa, autologous stem-cell transplantation and response-adapted whole-brain radiotherapy: results of the multicenter Ostdeutsche Studiengruppe Hamato-Onkologie OSHO-53 phase II study. Ann. Oncol. 18, 665-671 (2007).
5. Batchelor, T. et al. Treatment of primary CNS lymphoma with methotrexate and deferred radiotherapy: a report of NABTT 96-07. J. Clin. Oncol. 21, 1044-1049 (2003).
6. Herrlinger, U. et al. NOA-03 trial of high-dose methotrexate in primary central nervous system lymphoma: final report. Ann. Neurol. 57, 843-847 (2005). (Pubitemid 40798622)
7. Ferreri, A. J. et al. High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial. Lancet 374, 1512-1520 (2009).
8. Coiffier, B. State-of-the-art therapeutics: diffuse large B-cell lymphoma. J. Clin. Oncol. 23, 6387-6393 (2005). (Pubitemid 46218851)
9. Correa, D. D. et al. Cognitive functions in primary central nervous system lymphoma: literature review and assessment guidelines. Ann. Oncol. 18, 1145-1151 (2007).
10. Ferreri, A. J. et al. Prognostic scoring system for primary CNS lymphomas: the International Extranodal Lymphoma Study Group experience. J. Clin. Oncol. 21, 266-272 (2003).